ApoA1: what your result means.

The main protein in HDL; reflects the body's cholesterol-clearing capacity. ApoA1 is measured by blood test as part of the Cardiovascular panel in the HodieLabs Health Blueprint.

Why ApoA1 matters

ApoA1 measures HDL particle number, complementing HDL-C which measures cholesterol content. The ApoB/ApoA1 ratio integrates atherogenic and protective particles into a single metric.

Associated risks when out of range: Low ApoA1 reflects reduced HDL particle count and impaired reverse cholesterol transport, ApoB/ApoA1 ratio is a powerful composite cardiovascular risk marker.

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets ApoA1, from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• AMORIS study (Walldius et al. The Lancet 2001): in ~175,000 Swedish adults, low ApoA1 combined with high ApoB substantially improved prediction of fatal myocardial infarction over conventional lipids, establishing the apolipoprotein pair as superior risk measures.
• INTERHEART study (Yusuf et al. The Lancet 2004): the ApoB/ApoA1 ratio, in which ApoA1 is the protective denominator, was the strongest single modifiable risk factor for heart attack across 52 countries.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets ApoA1 against published clinical authority standards, never arbitrary "optimal" ranges. Measured in g/L:

Clinical interpretation

• ApoA1 measures HDL particle number, complementing HDL-C which measures cholesterol content.
• The ApoB/ApoA1 ratio integrates atherogenic and protective particles into a single metric.

What improves it: the evidence-based levers

• Exercise
• Diet quality
• Weight optimisation

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How ApoA1 testing works at HodieLabs

ApoA1 is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. Walldius G, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study). Lancet. 2001;358:2026–2033.
2. Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART). Lancet. 2004;364:937–952.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.